Cancer research at HonorHealth

Clinical Trials

Call 480-323-1339 or send an email.

Cancer care is a fast-evolving field, with constant advances in the quest for a cure. Participating in the HonorHealth Virginia G. Piper Cancer Care Network’s research programs gives you access to the latest innovative cancer treatment options possible.

Why should you participate in cancer research?

Reasons to become a clinical trial participant include:

  • The possibility of access to a new medication before it’s FDA approved and available to the public.
  • Learning more about your disease or condition and the latest advances in treatment.
  • Being closely monitored by the study coordinator and physician.
  • Contributing to the advancement of medical care.

Cancer research eligibility

A clinical trial is an option for cancer patients at any stage of their cancer journey. In fact, it is recommended that you seek out a clinical trial as soon as you’re diagnosed. You don’t have to wait until other treatments have failed to enroll in a trial. However, you must have completed at least one standard treatment prior to consideration.

Each clinical trial has specific eligibility criteria — requirements you must meet before you can participate. The clinical trials nurse navigators will help you make a decision. Contact a navigator at 480-323-1339, 877-273-3713 or via email

Cancer research advancements at HonorHealth

The HonorHealth Research Institute coordinates cancer research. The institute is changing how the world treats cancer through the development of new cancer drugs and fast-tracking their FDA approval. Research advancements include:

  • In September 2013, the FDA approved the combination of Abraxane and Gemcitibine to treat advanced pancreatic cancer after HonorHealth researchers led a successful international clinical trial around the approach. The drug, now standard of care, is one of six that the HonorHealth Research Institute has brought to market in record time in the last 10 years.
  • Erivedge, the first drug to receive expedited FDA approval for treating inoperable basal cell carcinoma, went from Phase I clinical trials at HonorHealth to FDA approval in five years. Normal time from research to FDA approval can be up to 15 years.
  • RADAR (Rapid Detection and Assessment of Response) is a one-of-a-kind rapid cancer detection program developed through collaboration between local physicians and the HonorHealth Research Institute.
  • Stand Up to Cancer twice selected HonorHealth as a Dream Team site for cancer research. The HonorHealth Research Institute is the only cancer program in the Southwest participating as a collaborator in the multimillion-dollar Stand Up to Cancer pancreatic cancer Dream Team grants. Researchers here have been conducting clinical trials of new treatments designed to cut off the fuel supply of nutrients that feed pancreatic cancer cell growth.
  • Researchers identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy. The discovery is critical because patients with small-cell lung cancer often do not get a second chance at therapies to combat the aggressive form of cancer.
  • HonorHealth was the first site in the world for clinical trials of a new drug called OSI-906 to combat adrenocortical carcinoma, a rare but deadly cancer that attacks the adrenal glands.